EU approval for Tecentriq combo
The approval of the monoclonal antibody was based on results from the Phase III IMpassion130 study.
Read More
Tag: nab-paclitaxel
UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.
Read More
Pancreatic cancer patients in England get CDF access to Abraxane
Patients with pancreatic cancer living in England can from today potentially get access to a new treatment option after funding for Celgene’s Abraxane was approved for NHS use.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
